NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer

Reuters

05-22

<a href="https://laohu8.com/S/NEO">NeoGenomics</a> Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer

NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry $(IHC)$ assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537481459"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537481459\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537481459?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537481459","market":"nz","top_or_hot":-1,"title":"NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry <a href=\"https://laohu8.com/S/IHC\">$(IHC)$</a> assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-22 19:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry <a href=\"https://laohu8.com/S/IHC\">$(IHC)$</a> assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL9m7sp3:1","article_id":"2537481459","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537481459","pubTimestamp":1747912212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire  on May 22, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"NeoGenomics Inc.推出用于晚期非小细胞肺癌快速治疗指导的c-MET CDx检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":0.9},"content_text":"NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n    \n\n        NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry $(IHC)$ assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}